Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EBITDA (2018 - 2025)

BioNexus Gene Lab's EBITDA history spans 8 years, with the latest figure at -$705775.0 for Q3 2025.

  • For Q3 2025, EBITDA fell 136.38% year-over-year to -$705775.0; the TTM value through Sep 2025 reached -$2.6 million, down 12295.43%, while the annual FY2024 figure was -$1.5 million, 49.05% up from the prior year.
  • EBITDA for Q3 2025 was -$705775.0 at BioNexus Gene Lab, down from -$249094.0 in the prior quarter.
  • Across five years, EBITDA topped out at $431764.0 in Q4 2023 and bottomed at -$2.6 million in Q3 2023.
  • The 5-year median for EBITDA is -$249094.0 (2025), against an average of -$317184.3.
  • The largest annual shift saw EBITDA skyrocketed 169.46% in 2021 before it tumbled 2294.97% in 2022.
  • A 5-year view of EBITDA shows it stood at $128173.0 in 2021, then skyrocketed by 88.31% to $241359.0 in 2022, then skyrocketed by 78.89% to $431764.0 in 2023, then crashed by 346.75% to -$1.1 million in 2024, then soared by 33.75% to -$705775.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's EBITDA are -$705775.0 (Q3 2025), -$249094.0 (Q2 2025), and -$551168.0 (Q1 2025).